Objective To evaluate the effect of art therapy on cancer patients' quality of life and physical and psychological symptoms. Methods The databases PubMed, Embase, Web of Science, The Cochrane Library, Clinical Trial.gov, the China National Knowledge Infrastructure (CNKI), Wanfang and the Chinese Biomedical Literature Database (CBM) were searched from their inception up to 20 August 2019. Trials examining the effects of art therapy on physical and psychological symptoms and quality of life versus a control group were included. The methodological quality of the included randomised controlled trials was assessed using the risk of bias tool of Cochrane Handbook. Meanwhile, the Newcastle-Ottawa Quality Assessment Scale (NOS) was used to evaluate the methodological quality of the non-randomised studies. Results Twelve studies involving 587 cancer patients were included. The results revealed that art therapy significantly reduced anxiety symptoms (standard mean difference [SMD] = -0.46, 95% confidence interval [CI] [-0.90, 0.02], p = .04), depression symptoms (SMD = -0.47, 95% CI [-0.72, 0.21], p less then .01), and fatigue (SMD = -0.38, 95% CI [-0.68, -0.09], p = .01) in cancer patients. Art therapy also significantly improved the quality of life of cancer patients (SMD = 0.43, 95% CI [0.18, 0.68], p less then .01). Conclusions Art therapy had a positive effect on quality of life and symptoms in cancer patients and can be used as a complementary treatment for cancer patients.A quick, simple, and high-yield nucleic acid isolation process is crucial for high-quality DNA analysis. The ability of the MicroGEM PDQeX phytoGEM system and Omega Bio-tek E.Z.N.A.® Plant DS Mini kit to extract PCR-ready DNA was evaluated by extracting the forensically relevant "legal high" plant species Ipomoea purpurea, Artemisia absinthium, Mitragyna speciosa, Datura stramonium, and Papaver somniferum. The plant material was pulverized, processed using the manufacturer's plant protocol for the PDQeX Nucleic Acid Extraction or the manufacturer's protocol for the Omega extraction, quantified using the Invitrogen Qubit 2.0 Fluorometer, and analyzed for amplifiability by PCR using a Qiagen Rotor-Gene Q instrument and published assays. The DNA amplicons for the legal high species produced high-resolution melt curves concordant with the melts observed when DNA was isolated using the Qiagen DNeasy Plant Mini Kit in previous studies.Aims Intraductal carcinoma (IDC) is an adverse histopathological parameter for prostate cancer outcome, but not incorporated in current tumour grading. To account for its dismal prognosis and omit basal cell immunohistochemistry, it has been proposed to grade IDC based on its underlying architectural pattern. Our objective was to determine the impact of IDC grade assignment on prostate cancer biopsy and radical prostatectomy tumour grading. Methods and results A cohort of 1,031 prostate cancer biopsies and 835 radical prostatectomies was assigned a Grade Group according to the 2014 International Society of Urological Pathology (ISUP) guidelines, not incorporating IDC in grading. Tumour grading was compared with a Grade Group in which IDC was graded based on its underlying architecture. Out of 1,031 biopsies, 139 (13.5%) had IDC. Grade assignment to IDC led to a Grade Group change in 17 (1.6%) cases 4/486 (0.8%) Grade Group 1 were reclassified as Grade Group 2, 9/375 (2.4%) Grade Group 2 as 3, and 4/58 (6.9%) Grade Group 4 as 5. IDC was observed in 213/835 (25.5%) radical prostatectomies and its grading led to a shift in tumour grade in 5/835 (0.6%) men, with upgrading in 2/207 (1.0%) men with Grade Group 1, 2/420 (0.5%) with Grade Group 2, and 1/50 (2%) with Grade Group 4 cancer. Conclusion IDC grade assignment led to a Grade Group change in 1.6% of prostate biopsy and 0.6% of radical prostatectomy specimens. Although inclusion/exclusion of IDC from the Grade Group might affect decision-making in individual patients, it has minimal impact on overall prostate cancer management.Robert's uterus and bicornuate uterus are two different kinds of congenital uterine malformation. In the present study, the authors report a rare case of a 16-year-old girl diagnosed with hybrid Robert's uterus and bicornuate uterus, and unique ipsilateral renal agenesis. The authors performed a minimally invasive surgical procedure to obtain asymmetric uterine septum resection by combined hysteroscopy-laparoscopy. The patient was pregnant spontaneously one year after surgery and delivered a healthy baby by cesarean delivery.The objective of this study was to determine the pharmacokinetics of tildipirosin in rabbits after a single intravenous (i.v.) and intramuscular (i.m.) injection at a dose of 4 mg/kg.  https://www.selleckchem.com/products/VX-770.html  Twelve white New Zealand rabbits were assigned to a randomized, parallel trial design. Blood samples were collected prior to administration and up to 14 days postadministration. Plasma concentrations of tildipirosin were quantified using a validated ultra-high-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method. The pharmacokinetic parameters were calculated using a noncompartmental model in WinNonlin 5.2 software. Following i.v. and i.m. administration, the elimination half-life (T1/2λ ) was 81.17 ± 9.28 and 96.68 ± 15.37 hr, respectively, and the mean residence time (MRTlast ) was 65.44 ± 10.89 and 67.06 ± 10.49 hr, respectively. After i.v. injection, the plasma clearance rate (Cl) and volume of distribution at steady state (Vdss ) were 0.28 ± 0.10 L kg-1 h-1 and 17.78 ± 5.15 L/kg, respectively. The maximum plasma concentration (Cmax ) and time to reach maximum plasma concentration (Tmax ) after i.m. administration were 836.2 ± 117.9 ng/ml and 0.33 ± 0.17 hr, respectively. The absolute bioavailability of i.m. administration was 105.4%. Tildipirosin shows favorable pharmacokinetic characteristics in rabbits, with fast absorption, extensive distribution, and high bioavailability. These findings suggest that tildipirosin might be a potential drug for the prevention and treatment of respiratory diseases in rabbits.Aims Diffuse alveolar damage (DAD) is a ubiquitous finding in inpatient coronavirus disease 2019 (COVID-19)-related deaths, but recent reports also describe additional atypical findings, including vascular changes. Here, we assess lung autopsy findings in COVID-19 inpatients and untreated, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-positive individuals who died in the community to understand the relative impact of medical intervention on lung histology. Additionally, we investigate if COVID-19 represents a unique histologic variant of DAD by comparing the pathologic findings to uninfected control patients. Methods and results Lung sections from autopsy cases were reviewed by three pulmonary pathologists, including two who were blinded to patient cohort. The cohorts included 4 COVID-19 inpatients, 4 cases with post-mortem SARS-CoV-2 diagnoses who died in the community, and 8 SARS-CoV-2-negative control cases. DAD was present in all but one SARS-CoV-2-positive patient who was asymptomatic and died in the community.